# Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients

> **NCT05073484** · PHASE1 · TERMINATED · sponsor: **Bio-Thera Solutions** · enrollment: 13 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** BAT6021
- **DRUG:** BAT1308

## Key facts

- **NCT ID:** NCT05073484
- **Lead sponsor:** Bio-Thera Solutions
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-10-29
- **Primary completion:** 2023-03-30
- **Final completion:** 2023-03-30
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Based on the disclosed global research data on the same target drugs, the company has carefully considered and decided to terminate the project to optimize the existing research pipeline.
- **Last updated:** 2023-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05073484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05073484, "Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05073484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*